A Phase 2 interventional study of PF-05089771 150 mg and Matched placebo for PF-05089771 150 mg and pregabalin 300 mg in Diabetic Neuropathy, Painful, sponsored by Pfizer. Completed at 32 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-05-05.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing pregabalin in Diabetic Neuropathies — 1 open to participants now, 1 under way, 1 of them phase 3. Pregabalin · Diabetic Neuropathies.
Among the 17 studies testing pregabalin in Diabetic Neuropathies, this one is the 13th largest by enrollment, is the only one that started in 2014, is the only one in phase 2, and was the 16th registered.
539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.
Browse Diabetic Neuropathies studies →1 of the 17 studies testing pregabalin in Diabetic Neuropathies is open now, in 1 country. Recruiting first, the newest first:
Brainfarma Industria Química e Farmacêutica S/A · Sites in Brazil
Ages 18–75
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 141 is above the median of 68 across 449 interventional studies indexed under Diabetic Neuropathies.
Median enrollment 241 across the 17 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 7 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
10 studies in Diabetic Neuropathies by Pfizer: none open now, none under way, none of them phase 3. Of 10 finished, 5 (50%) have results posted.
Among the 10 studies in Diabetic Neuropathies by Pfizer, this one is the only one that started in 2014, is one of 4 in phase 2, and was the 10th registered.
Pfizer’s Diabetic Neuropathies studies by the year they started, since 1999.
1 of the studies testing pregabalin in Diabetic Neuropathies that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07712913Phase 3Brainfarma Industria Química e Farmacêutica S/AExtended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing pregabalin in Diabetic Neuropathies, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 10 in Diabetic Neuropathies:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of PF-05089771 as a monotherapy and as an add-on to pregabalin for the treatment of painful diabetic peripheral neuropathy (DPN)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PF-05089771 150 mg
Drug: Matched placebo for PF-05089771 150 mg and pregabalin 300 mg
Drug: Pregabalin 300 mg
Drug: PF-05089771 150 mg + Pregabalin 300 mg
PF-05089771 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
Matched placebo for PF-05089771 150 mg twice daily and pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
Pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
Drug page: PF-05089771
PF-05089771 150 mg twice daily oral capsules with pregabalin 150 mg twice daily oral capsules. Treatment period = 4 weeks.
Daily Pain Numeric Rating Scale (NRS)
The endpoint average pain score, based on the mean of the last 7 days' daily pain numeric rating scale (NRS) scores at (NRS is an 11-point scale where 0 = no pain and 10 = worst possible pain) from the daily pain diaries while receiving study medication during the treatment period.
Time frame: Baseline, Week 1, Week 2, Week 3 and Week 4
Responder Rate Based on a 30% Improvement in Mean Pain Response Using the Daily Pain NRS Score
Percentage of participants that received ≥30% improvement from baseline in mean pain response (from the daily pain diary).
Time frame: Baseline, Week 1, Week 2, Week 3 and Week 4
Responder Rate Based on a 50% Improvement in Mean Pain Response Using the Daily Pain NRS Score
Percentage of participants that received ≥50% improvement from baseline in mean pain response (from the daily pain diary).
Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4
Neuropathic Pain Symptom Inventory (NPSI) - Burning (Superficial) Spontaneous Pain
Participants rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.
Time frame: Baseline, Week 2, and Week 4
Neuropathic Pain Symptom Inventory (NPSI) - Pressing (Deep) Spontaneous Pain
Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.
Time frame: Baseline, Week 2 and Week 4
Neuropathic Pain Symptom Inventory (NPSI) - Paroxysmal Pain
Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.
Time frame: Baseline, Week 2, and Week 4
Neuropathic Pain Symptom Inventory (NPSI) - Evoked Pain
Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.
Time frame: Baseline, Week 2 and Week 4
Neuropathic Pain Symptom Inventory (NPSI) - Paresthesia/Dysethesia
Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.
Time frame: Baseline, Week 2 and Week 4
Neuropathic Pain Symptom Inventory (NPSI) - Total Score
Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.
Time frame: Baseline, Week 2 and Week 4
Patient's Global Impression of Change Score (PGIC).
Participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse) at week 4. The PGIC was combined to produce a 3-point scale, "Improved", "No Change" and "Worse".
Time frame: Baseline, Week 2, and Week 4
Daily Sleep Interference Scale Score (DSIS).
Participant rated 11-point Likert scale ranging from 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep) during past 24-hour period. Higher score indicates a greater level of sleep disturbance. Self-assessment performed daily on awakening prior to taking study medication. This score was measured as a weekly average.
Time frame: Baseline, Week 1, Week 2, Week 3 and Week 4
Total Amount of Rescue Medication Per Week
Total amount of rescue medication participants take per week
Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4
Number of Days Participants Take Rescue Medication
Number of days participants take rescue medication per week.
Time frame: Baseline, Week 1, Week 2, Week 3 and Week 4
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to Adverse Events (AEs)
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect.
Time frame: Screening to Day 36, and Day 64
Number of Participants With Laboratory Test Values of Potential Clinical Importance
The total number of participants with laboratory test abnormalities (without regard to baseline abnormality) was assessed. Clinical laboratory tests included hematology, chemistry, urinalysis and some other tests.
Time frame: Screening, Day 1, Day 15 and Day 29
Fasted Total Cholesterol Values
Percentage Change from Baseline in Fasted Total Cholesterol values
Time frame: Baseline, Week 2 and Week 4
Fasted Low Density Lipoprotein (LDL) Cholesterol
Percentage Change from Baseline in LDL cholesterol Friedewald by PEG
Time frame: Baseline, Week 2 and Week 4
Plasma Concentration of PF-05089771
All participants in this group were analysed. Only plasma PK concentration of PF-05089771 was analysed.
Time frame: Baseline, Week 2 and Week 4
Eligibility included healthy male and/or female participants of non childbearing potential between the ages of 18 and 80 years, inclusive, and a diagnosis of painful diabetic peripheral neuropathy and type II diabetes. Following the interim analysis, the study was stopped. No participants were dosed with PF-05089771 150mg BID + pregabalin.
| Milestone | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Started | 44 | 46 | 45 |
| Completed | 42 | 38 | 41 |
| Not completed | 2 | 8 | 4 |
| Withdrew: Adverse event | 1 | 5 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Does not meet entrance criteria | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 1 |
The endpoint average pain score, based on the mean of the last 7 days' daily pain numeric rating scale (NRS) scores at (NRS is an 11-point scale where 0 = no pain and 10 = worst possible pain) from the daily pain diaries while receiving study medication during the treatment period.
| Unit on a scale | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Baseline (n = 44, 46, 45) | 6.17 ± 1.164 | 6.62 ± 1.420 | 6.35 ± 1.170 |
| Week 1 (n = 44, 46, 44) | 5.45 ± 1.372 | 5.87 ± 1.872 | 6.07 ± 1.454 |
| Week 2 (n = 43, 44, 40) | 5.14 ± 1.762 | 5.26 ± 2.302 | 6.10 ± 1.504 |
| Week 3 (n = 38, 40, 41) | 5.01 ± 1.820 | 5.36 ± 2.386 | 5.76 ± 1.540 |
| Week 4 (n = 41, 38, 39) | 4.83 ± 1.595 | 5.14 ± 2.508 | 5.61 ± 1.820 |
Percentage of participants that received ≥30% improvement from baseline in mean pain response (from the daily pain diary).
| Percentage of participants | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Week 1 (n = 44, 46, 45) | 9.09 | 15.22 | 4.44 |
| Week 2 (n = 44, 45, 44) | 22.73 | 31.11 | 9.09 |
| Week 3 (n = 42, 42, 43) | 23.81 | 26.19 | 11.63 |
| Week 4 (n = 42, 38, 43) | 28.57 | 31.58 | 16.28 |
Percentage of participants that received ≥50% improvement from baseline in mean pain response (from the daily pain diary).
| Percentage of participants | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Week 1 (n = 44, 46, 45) | 0 | 4.35 | 4.44 |
| Week 2 (n = 44, 45, 44) | 11.36 | 15.56 | 2.27 |
| Week 3 (n = 42, 42, 43) | 7.14 | 19.05 | 2.33 |
| Week 4 (n = 42, 38, 43) | 9.52 | 23.68 | 6.98 |
Participants rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.
| Unit on a scale | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Baseline (n = 44, 46, 45) | 4.6 ± 2.71 | 5.3 ± 2.49 | 4.8 ± 2.35 |
| Week 2 (n = 42, 41, 43) | 3.7 ± 2.94 | 4.3 ± 3.06 | 4.2 ± 2.35 |
| Week 4 (n = 42, 38, 42) | 3.4 ± 3.04 | 4.3 ± 2.80 | 4.5 ± 2.55 |
Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.
| Unit on a scale | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Baseline (n = 44, 46, 45) | 3.8 ± 2.48 | 4.9 ± 2.21 | 4.5 ± 2.40 |
| Week 2 (n = 42, 41, 43) | 3.3 ± 2.51 | 4.4 ± 2.83 | 4.2 ± 2.33 |
| Week 4 (n = 42, 38, 42) | 3.4 ± 2.67 | 3.9 ± 3.08 | 4.0 ± 2.48 |
Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.
| Unit on a scale | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Baseline (n = 44, 46, 45) | 4.5 ± 2.36 | 5.8 ± 2.18 | 5.6 ± 2.23 |
| Week 2 (n = 42, 41, 43) | 4.1 ± 2.61 | 4.7 ± 2.98 | 4.9 ± 2.11 |
| Week 4 (n = 42, 38, 42) | 3.9 ± 2.87 | 4.6 ± 2.83 | 4.8 ± 2.55 |
Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.
| Unit on a scale | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Baseline (n = 44, 45, 45) | 2.7 ± 2.38 | 5.0 ± 2.51 | 4.2 ± 2.42 |
| Week 2 (n = 42, 40, 43) | 2.0 ± 1.92 | 4.0 ± 2.67 | 3.5 ± 2.47 |
| Week 4 (n = 42, 37, 42) | 2.3 ± 2.24 | 3.8 ± 3.07 | 3.6 ± 2.53 |
Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.
| Unit on a scale | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Baseline (n = 44, 46, 45) | 5.7 ± 2.02 | 6.1 ± 2.35 | 6.6 ± 1.96 |
| Week 2 (n = 42, 41, 43) | 4.8 ± 2.45 | 5.3 ± 2.83 | 5.9 ± 2.40 |
| Week 4 (n = 42, 38, 42) | 4.9 ± 2.34 | 5.4 ± 2.84 | 5.9 ± 2.63 |
Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.
| Unit on a scale | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Baseline (n = 44, 45, 45) | 40.6 ± 17.33 | 53.4 ± 19.35 | 50.7 ± 16.87 |
| Week 2 (n = 42, 40, 34) | 34.2 ± 17.39 | 44.6 ± 24.64 | 44.7 ± 18.11 |
| Week 4 (n = 42, 37, 42) | 34.7 ± 19.40 | 42.7 ± 27.23 | 44.5 ± 20.18 |
Participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse) at week 4. The PGIC was combined to produce a 3-point scale, "Improved", "No Change" and "Worse".
| Number of participants | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Improved (Baseline, n = 43, 46, 45) | 20 | 11 | 16 |
| Improved (Week 2, n = 42, 41, 43) | 27 | 30 | 26 |
| Improved (Week 4, n = 42, 38, 42) | 28 | 27 | 24 |
| No change (Baseline, n = 43, 46, 45) | 19 | 30 | 25 |
| No change (Week 2, n = 42, 41, 43) | 10 | 7 | 13 |
| No change (Week 4, n = 42, 38, 42) | 12 | 9 | 14 |
| Worse (Baseline, n = 43, 46, 35) | 4 | 5 | 4 |
| Worse (Week 2, n = 42, 41, 43) | 5 | 4 | 4 |
| Worse (Week 4, n = 42, 38, 42) | 2 | 2 | 4 |
Participant rated 11-point Likert scale ranging from 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep) during past 24-hour period. Higher score indicates a greater level of sleep disturbance. Self-assessment performed daily on awakening prior to taking study medication. This score was measured as a weekly average.
| number on a scale | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Baseline (n = 44, 46, 45) | 4.7 ± 2.42 | 5.6 ± 2.38 | 4.9 ± 2.29 |
| Week 1 (n= 44, 46, 44) | 4.1 ± 2.29 | 4.7 ± 2.55 | 4.7 ± 2.46 |
| Week 2 (n = 43, 44, 40) | 4.0 ± 2.33 | 4.1 ± 2.74 | 4.7 ± 2.41 |
| Week 3 (n = 38, 40, 41) | 3.6 ± 2.28 | 4.4 ± 2.71 | 4.3 ± 2.49 |
| Week 4 (n = 41, 38, 39) | 3.4 ± 2.13 | 4.2 ± 2.82 | 4.3 ± 2.51 |
Total amount of rescue medication participants take per week
| mg | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Baseline (n = 44, 46, 45) | 2726 ± 4310 | 3398 ± 5723 | 1863 ± 3684 |
| Week 1 (n = 44, 46, 45) | 2272 ± 4043 | 2897 ± 5605 | 1694 ± 3425 |
| Week 2 (n = 44, 45, 44) | 1669 ± 3248 | 2952 ± 5488 | 1391 ± 3238 |
| Week 3 (n = 42, 42, 43) | 1851 ± 3228 | 1885 ± 4918 | 1306 ± 3308 |
| Week 4 (n = 42, 38, 43) | 1617 ± 2945 | 2328 ± 5256 | 1372 ± 3307 |
Number of days participants take rescue medication per week.
| days | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Baseline (n = 44, 46, 45) | 2.8 ± 3.49 | 2.1 ± 3.02 | 1.6 ± 2.60 |
| Week 1 (n = 44, 46, 45) | 2.3 ± 3.16 | 1.8 ± 2.74 | 1.5 ± 2.50 |
| Week 2 (n = 44, 45, 44) | 2.0 ± 3.08 | 1.7 ± 2.63 | 1.2 ± 2.25 |
| Week 3 (n = 42, 42, 43) | 2.1 ± 3.00 | 1.2 ± 2.35 | 1.0 ± 2.10 |
| Week 4 (n = 42, 38, 43) | 1.9 ± 2.80 | 1.6 ± 2.55 | 1.1 ± 2.28 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect.
| Participants | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Participants with TEAEs | 16 | 24 | 17 |
| Participants with SAE | 1 | 1 | 0 |
| Withdrawals due to AEs | 1 | 5 | 2 |
The total number of participants with laboratory test abnormalities (without regard to baseline abnormality) was assessed. Clinical laboratory tests included hematology, chemistry, urinalysis and some other tests.
| Participants | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Number of Participants With Laboratory Test Values of Potential Clinical Importance | 38 | 35 | 37 |
Percentage Change from Baseline in Fasted Total Cholesterol values
| Percent change | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Week 2 (n = 41, 37, 41) | 3.46 ± 12.279 | -1.45 ± 10.242 | -0.43 ± 14.271 |
| Week 4 (n = 40, 33, 39) | 6.59 ± 15.618 | -0.11 ± 10.023 | -1.71 ± 14.242 |
Percentage Change from Baseline in LDL cholesterol Friedewald by PEG
| Perecent change | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| Week 2 (n = 38, 34, 39) | 8.17 ± 23.849 | -1.73 ± 14.496 | 0.81 ± 22.900 |
| Week 4 (n = 37, 31, 36) | 13.61 ± 29.729 | 0.85 ± 13.512 | 1.48 ± 19.804 |
All participants in this group were analysed. Only plasma PK concentration of PF-05089771 was analysed.
| ng/ml | PF-05089771 150 mg BID |
|---|---|
| Baseline (n = 43) | NA ± NA |
| Week 2 (n = 41) | 7673 ± 4861 |
| Week 4 (n = 41) | 8784 ± 5749 |
Collected over From first dose of placebo run-in until 28 days after last dose of placebo run-out, an average of 3 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-05089771 150 mg BID | — | 1/44 (2.3%) | 3/44 (6.8%) |
| Pregabalin | — | 1/46 (2.2%) | 12/46 (26.1%) |
| Placebo | — | 0/45 (0%) | 10/45 (22.2%) |
| Event | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/44 | 0/46 | 0/45 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/44 | 0/46 | 0/45 |
| Cardiac failure congestiveCardiac disorders | 0/44 | 1/46 | 0/45 |
| Event | PF-05089771 150 mg BID | Pregabalin | Placebo |
|---|---|---|---|
| DizzinessNervous system disorders | 0/44 | 5/46 | 2/45 |
| HeadacheNervous system disorders | 2/44 | 3/46 | 4/45 |
| Upper respiratory tract infectionInfections and infestations | 1/44 | 1/46 | 3/45 |
| NauseaGastrointestinal disorders | 0/44 | 3/46 | 1/45 |
| Vulvovaginal pruritusReproductive system and breast disorders | 0/17 | 1/19 | 0/14 |
The safety analysis set consisted of all participants who received at least one dose of study medication.
| Age, Continuous(years) | PF-05089771 150 mg BID | Pregabalin | Placebo | Total |
|---|---|---|---|---|
| Mean | 59.3 ± 9.4 | 58.1 ± 11.3 | 59.2 ± 10.9 | 58.9 ± 10.5 |
| Sex: Female, Male(Participants) | PF-05089771 150 mg BID | Pregabalin | Placebo | Total |
|---|---|---|---|---|
| Female | 17 | 19 | 14 | 50 |
| Male | 27 | 27 | 31 | 85 |
Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests
Ran from Nov 2014 to primary completion in Jul 2015, 8 months.
Results were first posted in May 2017, 1 year 9 months after primary completion.
Of 25 phase 2 interventional studies under Diabetic Neuropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 35. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PF-05089771 · Pregabalin